Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response

April 2023 in “ Journal of the American Academy of Dermatology ”

Ahmed Kazmi, Anthony Moussa, Laita Bokhari, Bevin Bhoyrul, Shobha Joseph, Vijaya Chitreddy, Samantha Eisman, Nekma Meah, Rodney Sinclair

tofacitinib baricitinib alopecia areata Xeljanz Olumiant

From the encyclopedia

Tofacitinib →

a JAK inhibitor for alopecia areata and other autoimmune conditions

Baricitinib →

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

We don't know much about this study yet.

View this study on jaad.org →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?

29 citations , December 2019 in “Expert review of clinical pharmacology”

This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.